Of particular significance for CNS specialist Biogen (Nasdaq: BIIB), industry analyst GlobalData has released a report highlighting higher levels of competition in the multiple sclerosis space.
Plegridy (peginterferon beta-1a), the only pegylated interferon approved for use in relapsing MS, was first approved in Europe in 2014, with a new intramuscular (IM) version picking up approval in late 2020.
The company recently announced it had also won US Food and Drug Administration approval for the IM version.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze